Literature DB >> 34740951

PET with a 68Ga-Labeled FAPI Dimer: Moving Toward Theranostics.

Muhsin H Younis1, Xiaoli Lan2,3, Weibo Cai4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34740951      PMCID： PMC9157727          DOI： 10.2967/jnumed.121.263292

Source DB:  PubMed          Journal:  J Nucl Med        ISSN： 0161-5505            Impact factor:   11.082


× No keyword cloud information.
  6 in total

1.  Usefulness of [68Ga]Ga-DOTA-FAPI-04 PET/CT in patients presenting with inconclusive [18F]FDG PET/CT findings.

Authors:  Haojun Chen; Liang Zhao; Dan Ruan; Yizhen Pang; Bing Hao; Yaqing Dai; Xiurong Wu; Wei Guo; Chunlei Fan; Jingxun Wu; Weipeng Huang; Qin Lin; Long Sun; Hua Wu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-06-25       Impact factor: 9.236

2.  Albumin Binder-Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy.

Authors:  Mengxin Xu; Pu Zhang; Jie Ding; Junyi Chen; Li Huo; Zhibo Liu
Journal:  J Nucl Med       Date:  2021-09-30       Impact factor: 11.082

3.  The Latest Developments in Imaging of Fibroblast Activation Protein.

Authors:  Annette Altmann; Uwe Haberkorn; Jens Siveke
Journal:  J Nucl Med       Date:  2020-10-30       Impact factor: 10.057

4.  [68Ga]Ga-DOTA-FAPI-04 improves tumor staging and monitors early response to chemoradiotherapy in a patient with esophageal cancer.

Authors:  Liang Zhao; Shanyu Chen; Li'e Lin; Long Sun; Hua Wu; Qin Lin; Haojun Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-04-24       Impact factor: 9.236

5.  Feasibility and Therapeutic Potential of 177Lu-Fibroblast Activation Protein Inhibitor-46 for Patients With Relapsed or Refractory Cancers: A Preliminary Study.

Authors:  Majid Assadi; Seyed Javad Rekabpour; Esmail Jafari; GhasemAli Divband; Babak Nikkholgh; Hamidreza Amini; Hassan Kamali; Sakineh Ebrahimi; Nader Shakibazad; Narges Jokar; Iraj Nabipour; Hojjat Ahmadzadehfar
Journal:  Clin Nucl Med       Date:  2021-07-14       Impact factor: 7.794

6.  Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177Lu-FAP-2286: First-in-Humans Results.

Authors:  Richard P Baum; Christiane Schuchardt; Aviral Singh; Maythinee Chantadisai; Franz C Robiller; Jingjing Zhang; Dirk Mueller; Alexander Eismant; Frankis Almaguel; Dirk Zboralski; Frank Osterkamp; Aileen Hoehne; Ulrich Reineke; Christiane Smerling; Harshad R Kulkarni
Journal:  J Nucl Med       Date:  2021-06-24       Impact factor: 10.057
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.